Eli Lilly has announced results from the VIVID-2 open-label extension study, showing that most patients with moderately to ...

Boehringer Ingelheim today revealed that the FIBRONEER-ILD trial of nerandomilast met its primary endpoint, which was the ...

New Jersey, USA-based clinical-stage biotech Imunon has appointed Dr Douglas Faller as chief medical officer, effective 18, ...

In a statement on Friday, the USA’s National Institutes of Health (NIH) said it would cut grants for "indirect costs" related ...

Pliant Therapeutics, a Californian biopharma focused on discovering and developing fibrosis drugs, saw its shares close down ...

A new bill has been presented for a pilot scheme that will allow pharmaceutical companies in Denmark to negotiate ...

France-based biopharma company Medincell this morning revealed it is to receive a $5 million development milestone from ...

On Sunday night, one of the USA’s largest compounders, Hims & Hers, ran a multi-million dollar Super Bowl advert about its provision of GLP-1 weight loss medications.

The Indian subsidiary of French pharma major Sanofi has received marketing authorization for Rezurock (belumosudil tablets) in India.

The ORPHAN Cures Act (HR 946), a bipartisan bill that removes barriers to treating and curing rare diseases, was reintroduced in the US House of Representative last week.

News last week including US biotechs Alumis and Acelyrin announcing that they are merging to create a late-stage clinical ...

Marking World Cancer Day 2025, this week's Executive Q&A is with Diego Santoro, General Manager & Head of International ...